Table 2.

Cox regression analysis

	HR (95% CI)
Sex
Male vs female	0.92 (0.58–1.46) p = 0.73
Age
> 62 vs < 62	0.70 (0.44–1.12) p = 0.13
BRAF
mut vs wt	1.06 (0.66–1.70) p = 0.81
LDH
High vs normal	1.62 (0.86–3.04) p = 0.13
Very high vs normal	4.64 (2.52–8.54) p < 0.0001
Brain metastasis
Yes vs no	1.92 (1.18–3.11) p = 0.008
Previous lines of treatment
2 vs 1	1.12 (0.62–2.02) p = 0.69
≥ 3 vs 1	1.38 (0.75–2.54) p = 0.30
Metastatic site
Lung vs soft tissue	0.76 (0.30–1.87) p = 0.54
Visceral vs soft tissue	1.85 (0.93–3.65) p = 0.08
Absolute lymphocyte count	0.87 (0.60–1.25) p = 0.45
Relative lymphocyte count (≥ 20 vs < 20)	0.96 (0.93–0.98) p = 0.001
Relative monocyte count	0.94 (0.82–1.06) p = 0.32
Relative eosinophil count (≥ 1.5 vs < 1.5)	0.75 (0.62–0.92) p = 0.006
Absolute neutrophil count (≥ 8 vs < 8)	1.11 (1.04–1.17) p = 0.001
Relative neutrophil count (≥ 70 vs < 70)	1.04 (1.01–1.06) p = 0.001
NLR	1.04 (1.02–1.06) p < 0.0001
dNLR	1.09 (1.04–1.14) p < 0.0001
Tot CD8+ cells
≥ 25.1 vs < 25.1	1.37 (0.86–2.18) p = 0.18
CD8+CD73+ cells (≥ 5.8 vs < 5.8)	1.55 (0.97–2.48) p = 0.07
CD8+PD-1+ cells (≥ 9.8 vs < 9.8)	1.86 (1.17–2.98) p = 0.009
CD8+PD-1+CD73+ cells (≥ 2.3 vs < 2.3)	2.25 (1.39–3.63) p = 0.001

HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, NLR neutrophil-to-lymphocyte ratio, dNLR derived NLR